Clinical Trial Details

< Previous Trial     Next Trial >
Study ID EA 4/033/06
Martin Schostak, PD Dr.,   University Medical Centre Charité, Berlin, Germany
André Schrattenholz, Prof. Dr.,   ProteoSys AG, Mainz, Germany
Title Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma
Conditions Prostate Cancer
Benign Prostatic Hyperplasia
Prostatic Intraepithelial Neoplasia
Phase N/A
Purpose Emerging from a differential proteomic study of sample pairs of prostate cancer and benign tissue, annexin A3 (ANXA3) was chosen as a potential novel biomarker for the early and non-invasive diagnosis of prostate cancer. We wanted to show or investigate, that: - ANXA3 can be detected in urine after standard digital rectal examination. - ANXA3 has better specificities than tPSA, in particular in the grey zone of PSA - ANXA3 can help avoid unnecessary biopsies - ANXA3 can in the long run replace PSA as a marker
Eligibility Ages Eligible: N/A
Genders Eligible:  Male
Accepts Healthy Volunteers:  No
Inclusion Criteria:
  • Patients with a histological confirmation of adenocarcinoma of the prostate
  • Patients with benign prostatic hyperplasia (confirmed by histology of lance biopsies or TUR-P) Exclusion Criteria:
  • Patients with rectal extirpation
  • Patients with renal or bladder tumors
  • Study Location N/A
    Contact N/A

    Information obtained from, on 7/29/2015. For additional information about this and other clinical trials, visit
    Please refer to this study by its identifier: NCT00400894

    Back to Search Results